LV13469B - Treatment of latent tuberculosis - Google Patents

Treatment of latent tuberculosis Download PDF

Info

Publication number
LV13469B
LV13469B LVP-05-161A LV050161A LV13469B LV 13469 B LV13469 B LV 13469B LV 050161 A LV050161 A LV 050161A LV 13469 B LV13469 B LV 13469B
Authority
LV
Latvia
Prior art keywords
alkyl
phenyl
hydrogen
use according
formula
Prior art date
Application number
LVP-05-161A
Other languages
English (en)
Latvian (lv)
Inventor
Koenraad Jozef Lodewij Andries
Anil Koul
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35717702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV13469(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of LV13469B publication Critical patent/LV13469B/lv

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
LVP-05-161A 2004-12-24 2005-12-09 Treatment of latent tuberculosis LV13469B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04078529 2004-12-24
EP05105008 2005-06-08

Publications (1)

Publication Number Publication Date
LV13469B true LV13469B (en) 2007-01-20

Family

ID=35717702

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-05-161A LV13469B (en) 2004-12-24 2005-12-09 Treatment of latent tuberculosis

Country Status (31)

Country Link
US (1) US20060142279A1 (et)
EP (1) EP1830850B1 (et)
CN (1) CN103142595B (et)
AP (1) AP2327A (et)
AR (1) AR051790A1 (et)
AT (1) ATE501721T1 (et)
AU (1) AU2005242138B2 (et)
BR (1) BRPI0506400B8 (et)
CA (1) CA2529265C (et)
CR (1) CR9267A (et)
CY (1) CY1112247T1 (et)
DE (1) DE602005026984D1 (et)
DK (1) DK1830850T3 (et)
EE (1) EE05394B1 (et)
HK (1) HK1186125A1 (et)
HR (1) HRP20110392T1 (et)
IL (1) IL184123A (et)
LV (1) LV13469B (et)
ME (1) ME01207B (et)
MY (1) MY145845A (et)
NI (1) NI200700146A (et)
NO (1) NO340376B1 (et)
NZ (1) NZ555460A (et)
PA (1) PA8654801A1 (et)
PL (1) PL1830850T3 (et)
PT (1) PT1830850E (et)
RS (1) RS51730B (et)
SI (1) SI1830850T1 (et)
TR (1) TR200504892A1 (et)
TW (1) TWI404535B (et)
WO (1) WO2006067048A1 (et)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL222801B1 (pl) * 2002-07-25 2016-09-30 Janssen Pharmaceutica Nv Pochodne chinoliny, ich zastosowanie, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca je
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
ES2610472T3 (es) * 2005-06-28 2017-04-27 Janssen Pharmaceutica Nv Derivados de quinolina como agentes antibacterianos
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2970B1 (en) 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
US20110059948A1 (en) * 2008-01-14 2011-03-10 Jyoti Chattopadhyaya Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivatives as anti-mycobacterial agents
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
US8741917B2 (en) 2009-01-15 2014-06-03 Rutgers, The State University Of New Jersey Benzo [C] phenanthridines as antimicrobial agents
WO2010127307A1 (en) 2009-04-30 2010-11-04 Rutgers, The State University Of New Jersey Antimicrobial agents
US8933096B2 (en) 2010-06-09 2015-01-13 Rugers, The State University of New Jersey Antimicrobial agents
WO2011163610A2 (en) * 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2013106756A2 (en) 2012-01-13 2013-07-18 Rutgers, The State University Of New Jersey Antimicrobial agents
US9475783B2 (en) 2012-03-21 2016-10-25 Rutgers, The State University Of New Jersey Antimicrobial agents
EA038350B1 (ru) 2012-04-27 2021-08-12 Янссен Фармацевтика Нв Антибактериальные хинолиновые производные
US9133167B2 (en) 2012-04-27 2015-09-15 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
MD3250182T2 (ro) 2015-01-27 2023-09-30 Janssen Pharmaceutica Nv Compoziții dispersabile
WO2017147316A1 (en) 2016-02-25 2017-08-31 Taxis Pharmaceuticals, Inc. Synthetic processes and intermediates
CA3226824A1 (en) * 2016-03-07 2017-09-14 The Global Alliance For Tb Drug Development, Inc. Antibacterial compounds and uses thereof
RU2629369C1 (ru) * 2016-10-05 2017-08-29 Федеральное Государственное Унитарное Предприятие "Государственный Ордена Трудового Красного Знамени Научно-Исследовательский Институт Химических Реактивов И Особо Чистых Химических Веществ" Четвертичные аммонийные производные 2-аминотиофен-3-карбоксилатов, обладающие противотуберкулезной активностью
EP3600298A4 (en) 2017-03-30 2020-11-11 Taxis Pharmaceuticals, Inc. SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATE PRODUCTS
BR112020000687A2 (pt) 2017-07-14 2020-07-14 Janssen Pharmaceutica Nv formulações de longa ação
RU2661151C1 (ru) * 2017-12-14 2018-07-12 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Селективные ингибиторы глицеральдегид-3-фосфатдегидрогеназы микобактерий
JP2022516671A (ja) 2019-01-09 2022-03-01 ヤンセン ファーマシューティカ エヌ.ベー. 非結核性抗酸菌症の処置における組合せ
JP2023533014A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ.ベー. 長時間作用型配合物
EP4178541A1 (en) 2020-07-09 2023-05-17 JANSSEN Pharmaceutica NV Long-acting formulations
US20230346770A1 (en) 2020-11-12 2023-11-02 Janssen Pharmaceutica Nv Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038536A1 (es) * 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
PL222801B1 (pl) * 2002-07-25 2016-09-30 Janssen Pharmaceutica Nv Pochodne chinoliny, ich zastosowanie, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca je

Also Published As

Publication number Publication date
WO2006067048A1 (en) 2006-06-29
AU2005242138A1 (en) 2006-07-13
CY1112247T1 (el) 2015-12-09
ATE501721T1 (de) 2011-04-15
NI200700146A (es) 2019-05-10
BRPI0506400B8 (pt) 2021-05-25
PA8654801A1 (es) 2006-08-03
MY145845A (en) 2012-04-30
AU2005242138B2 (en) 2011-05-26
DE602005026984D1 (de) 2011-04-28
BRPI0506400A (pt) 2006-08-29
EE200500033A (et) 2006-08-15
DK1830850T3 (da) 2011-06-14
PT1830850E (pt) 2011-05-31
CR9267A (es) 2008-09-09
AR051790A1 (es) 2007-02-07
BRPI0506400B1 (pt) 2021-04-06
TW200637551A (en) 2006-11-01
PL1830850T3 (pl) 2011-07-29
EE05394B1 (et) 2011-04-15
BRPI0506400A8 (pt) 2017-09-12
IL184123A (en) 2011-10-31
US20060142279A1 (en) 2006-06-29
NZ555460A (en) 2008-11-28
IL184123A0 (en) 2008-12-29
AP2327A (en) 2011-11-25
HK1186125A1 (en) 2014-03-07
EP1830850A1 (en) 2007-09-12
NO20073823L (no) 2007-07-23
TR200504892A1 (tr) 2010-04-21
TWI404535B (zh) 2013-08-11
CN103142595B (zh) 2015-05-06
CN103142595A (zh) 2013-06-12
EP1830850B1 (en) 2011-03-16
HRP20110392T1 (hr) 2011-06-30
CA2529265A1 (en) 2006-06-24
SI1830850T1 (sl) 2011-07-29
ME01207B (me) 2013-03-20
RS51730B (en) 2011-10-31
CA2529265C (en) 2014-02-11
AP2007004054A0 (en) 2007-06-30
NO340376B1 (no) 2017-04-10

Similar Documents

Publication Publication Date Title
EP1830850B1 (en) Quinoline derivatives for the treatment of latent tuberculosis
EP1753427B1 (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
TW200410939A (en) Novel mycobacterial inhibitors
JP7233059B2 (ja) 結核に対する薬剤と組み合わせた環融合型チアゾリノ2-ピリドン
IL199083A (en) History of quinolonine antibacterial
JP2020509040A (ja) 併用療法
JP6426530B2 (ja) 潜伏性結核の処置
EP2099759B1 (en) Antibacterial quinoline derivatives
KR102442586B1 (ko) 고리-융합된 티아졸리노 2-피리돈, 이의 제조 방법 및 결핵의 치료 및/또는 예방에 있어서의 그 용도
MXPA05013413A (en) Treatment of latent tuberculosis